Image Place holder

Philippe Spiess, MD

Specialty: Urology
Program: Genitourinary Oncology


Cancer Focus: Bladder Cancer, Kidney (Renal Cell) Cancer, Penile Cancer, Testicular Cancer

Dr. Philippe Spiess is a genitourinary oncologist and the assistant chief of surgical services at the Moffitt Cancer Center. He is well a full professor of oncology and urology at the University of South Florida Morsani College of Medicine. Prior to joining Moffitt, Dr. Spiess completed a three-year SUO-accredited urologic oncology fellowship at the MD Anderson Cancer Center in Houston, Texas. Dr. Spiess’ research interests include novel therapies for advanced renal, bladder and penile cancer. Dr. Spiess has published over 220 peer reviewed manuscripts and has edited 5 textbooks on urologic oncology. Dr. Spiess currently serves as the vice-chair of the NCCN panel on bladder and penile cancer and sits on several international editorial boards including Urologic Oncology: Seminars and Original Investigations, BMC Urology, British Journal of Medicine and Medical Research, and the International Brazilian Journal of Urology. Dr. Spiess has delivered major lectures and seminars at national and international oncology meetings and has recently been appointed to serve on the American Urological Association Core Curriculum. A native of Canada, Dr. Spiess received a master’s in experimental urology surgery at McGill University in Montreal and his medical degree from the University of Toronto. He completed a urology residency at McGill University. Dr. Spiess is a fellow of the Royal College of Physicians and Surgeons in Canada and a member of the Société Internationale d’Urologie. He is fluent in English and French.

Education & Training


  • University of Texas MD Anderson Cancer Center, Houston, TX - Urologic Oncology


  • McGill University, Montreal, Canada - Urology

Medical School:

  • University of Toronto, Ontario, Canada - MD
Start Year: 2006 End Year: 2007 Course director, American Urological Association, Sponsor: American Urological Association
Start Year: 2014 End Year: 2015 Clinical Educator of the Year Award, Sponsor: Moffitt Cancer Center
Participating Trials

InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Condition: Genitourinary
Intervention: Ifosfamide (); Not Applicable (); Taxol (paclitaxel); cisplatin (); paclitaxel ()

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Bandini M, Ross JS, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ayres BA, Hakenberg OW, Heidenreich A, Salvioni R, Catanzaro M, Raggi D, Giannatempo P, Marandino L, Haidl F, Pederzoli F, Briganti A, Montorsi F, Chipollini J, Azizi M, De Meerleer G, Brouwer OR, Grass GD, Johnstone PA, Albersen M, Spiess PE, Necchi A. Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. Eur Urol Oncol. 2021 Oct.4(5):802-810. Pubmedid: 33199252.
  • Mir MC, Marchioni M, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, McGrath JS, Kassouf W, Dall'Era MA, Sridhar SS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand D, Black PC. Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium. Eur Urol Focus. 2021 Nov.7(6):1347-1354. Pubmedid: 32771446.
  • Khalil MI, Kamel MH, Dhillon J, Master V, Davis R, Hajiran AJ, Spiess PE. What you need to know: updates in penile cancer staging. World J Urol. 2021 May.39(5):1413-1419. Pubmedid: 32572556.
  • Rubino S, Kim Y, Zhou J, Dhillon J, Li R, Spiess P, Poch M, Manley BJ, Pow-Sang J, Gilbert S, Sexton W, Zhang J. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021 May.39(5):1539-1547. Pubmedid: 32656671.
  • Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, Rathmell WK, Daniels AB, Jonasch E, Spiess PE. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol. 2021 Jul.39(7):2409-2415. Pubmedid: 32936333. Pmcid: PMC8101019.
  • Ahmed ME, Falasiri S, Hajiran A, Chahoud J, Spiess PE. The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy. J Clin Med. 2020 Oct.9(10). Pubmedid: 33080912. Pmcid: PMC7603091.
  • Yuan Z, Yang GQ, Ahmed KA, Torres-Roca JF, Spiess PE, Johnstone PA. Radiation therapy in the management of the inguinal region in penile cancer: What's the evidence?. Urol Oncol. 2020 May. Pubmedid: 32482510.
  • Wang B, Gu W, Wan F, Wei Y, Xiao W, Lu X, Zhang G, Zhou J, Wang Q, Ding X, Azizi M, Spiess PE, Ye D, Zhu Y. Prognosis of the 8th TNM Staging System for Penile Cancer and Refinement of Prognostication by Incorporating High Risk Human Papillomavirus Status. J Urol. 2020 Mar.203(3):562-569. Pubmedid: 31596650.
  • Foerster B, Abufaraj M, Petros F, Azizi M, Gupta M, Schweitzer D, Margulis V, Iwata T, Kimura S, Shabsigh A, Briganti A, Ku JH, Muilwijk T, Kassouf W, Matin SF, Spiess PE, Pierorazio PM, Hendricksen K, Shariat SF. Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. J Urol. 2020 Jun.203(6):1101-1108. Pubmedid: 31898919.
  • Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE. Reply by Authors. J Urol. 2020 Jun.203(6):1155. Pubmedid: 32176595.
  • Ghahhari J, Marchioni M, Spiess PE, Chipollini JJ, Nyirády P, Varga J, Ditonno P, Boccasile S, Primiceri G, De Nunzio C, Tema G, Tubaro A, Veccia A, Antonelli A, Musi G, De Cobelli O, Conti A, Puliatti S, Micali S, Álvarez-Maestro M, Quesada Olarte J, Diogenes E, Lima MVA, Tracey A, Guruli G, Autorino R, Sountoulides P, Sosnowski R, Schips L, Cindolo L. Radical penectomy, a compromise for life: results from the PECAD study. Transl Androl Urol. 2020 Jun.9(3):1306-1313. Pubmedid: 32676414. Pmcid: PMC7354339.
  • Hajiran A, Bracco T, Zemp L, Spiess PE. Leveraging innovative therapies with an evolving understanding of the molecular pathogenesis of penile squamous cell carcinoma. Urol Oncol. 2020 Jul. Pubmedid: 32690436.
  • Spiess PE. Best videos of the year for 2019. Int Braz J Urol. 2020 Jan.46(1):3-4. Pubmedid: 31851452. Pmcid: PMC6968903.
  • Voskuilen CS, Schweitzer D, Jensen JB, Nielsen AM, Joniau S, Muilwijk T, Necchi A, Azizi M, Spiess PE, Briganti A, Bandini M, Goffin K, Bouchelouche K, van Werkhoven E, Shariat SF, Xylinas E, Azawi NH, Ku JH, Foerster B, van Rhijn BWG, Vegt E, Hendricksen K. Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2020 Feb.3(1):73-79. Pubmedid: 31591037.
  • Dreyfuss LD, Master VA, Raman JD, Spiess PE, Wells SA, Merrill SB, Peyton CC, Sankar D, Sohl B, Patil D, Shapiro DD, Allen GO, Abel EJ. Patterns of Initial Metastatic Recurrence After Surgery for High-Risk Nonmetastatic Renal Cell Carcinoma. Urology. 2020 Dec.146:152-157. Pubmedid: 32781079.
  • Kumar NB, Pow-Sang J, Spiess P, Dickinson S, Schell MJ. A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy. Oncotarget. 2020 Apr.11(14):1218-1234. Pubmedid: 32292572. Pmcid: PMC7147089.
  • Spiess PE, Greene J, Keenan RJ, Paculdo D, Letson GD, Peabody JW. Meeting the challenge of the 2019 novel coronavirus disease in patients with cancer. Cancer. 2020 Apr.126(14):3174-3175. Pubmedid: 32324273. Pmcid: PMC7264676.
  • Aydin AM, Cheriyan S, Spiess PE. Treating advanced penile cancer: where do we stand in 2019?. Curr Opin Support Palliat Care. 2019 Sep.13(3):249-254. Pubmedid: 31082941.
  • Necchi A, Ross JS, Spiess PE. Improving the Prognostic Ability for Personalized Therapeutic Approaches in Nonseminomatous Germ Cell Tumors. J Clin Oncol. 2019 Sep.37(26):2314-2316. Pubmedid: 31361537.
  • Chipollini J, da Costa WH, Werneck da Cunha I, de Almeida E Paula F, Guilherme O Salles P, Azizi M, Spiess PE, Abreu D, Zequi SC. Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies. Ther Adv Urol. 2019 Oct.11. Pubmedid: 31662794. Pmcid: PMC6792277.
  • Yuan Z, Grass GD, Azizi M, Ahmed KA, Yoder GSJ, Welsh EA, Fulp WJ, Dhillon J, Torres-Roca JF, Giuliano AR, Spiess PE, Johnstone PA. Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy. Rep Pract Oncol Radiother. 2019 Nov.24(6):593-599. Pubmedid: 31719799. Pmcid: PMC6839006.
  • Chipollini J, Garcia-Castaneda J, Rosa AH, Cheriyan S, Azizi M, Spiess PE. Important surgical concepts and techniques in inguinal lymph node dissection. Curr Opin Urol. 2019 May.29(3):286-292. Pubmedid: 30730389.
  • Kamel MH, Khalil MI, Davis R, Spiess PE. Management of the Clinically Negative (cN0) Groin Penile Cancer Patient: A Review. Urology. 2019 May.131:5-13. Pubmedid: 31129195.
  • Khalil MI, Wan F, Eltahawy E, Davis R, Spiess PE, Bissada NK, Kamel MH. Survival Following Salvage Surgery after Failed Radiotherapy for Penile Cancer: A SEER-Based Study. Curr Urol. 2019 May.12(3):142-146. Pubmedid: 31316322. Pmcid: PMC6613318.
  • Azizi M, Chipollini J, Peyton CC, Cheriyan SK, Spiess PE. Current controversies and developments on the role of lymphadenectomy for penile cancer. Urol Oncol. 2019 Mar.37(3):201-208. Pubmedid: 30301700.
  • Albersen M, Spiess P. Editorial: penile cancer. Curr Opin Urol. 2019 Mar.29(2):143-144. Pubmedid: 30601185.
  • Slongo J, Jain RK, Spiess PE. Important caveats of KEYNOTE-045: relevance of these findings in the current and future therapeutic paradigm. Ann Transl Med. 2019 Mar.7(Suppl 1):S23. Pubmedid: 31032303. Pmcid: PMC6462609.
  • Li R, Spiess PE, Gilbert SM, Necchi A. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. 2019 Jul.76(1):4-6. Pubmedid: 30833139.
  • Adashek JJ, Necchi A, Spiess PE. Updates in the molecular epidemiology and systemic approaches to penile cancer. Urol Oncol. 2019 Jul.37(7):403-408. Pubmedid: 31053523.
  • Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol. 2019 Jan.37(1):165-172. Pubmedid: 29882105.
  • Johnstone PAS, Spiess PE, Giuliano AR. New directions in penile cancer. Lancet Oncol. 2019 Jan.20(1):16-17. Pubmedid: 30573286.
  • Azizi M, Tang DH, Verduzco D, Peyton CC, Chipollini J, Yuan Z, Schaible BJ, Zhou JM, Johnstone PA, Giuliano A, Dhillon J, Spiess PE. Impact of PI3K-AKT-mTOR Signaling Pathway Up-regulation on Prognosis of Penile Squamous-Cell Carcinoma: Results From a Tissue Microarray Study and Review of the Literature. Clin Genitourin Cancer. 2019 Feb.17(1):e80-e91. Pubmedid: 30318447.
  • Zhu Y, Spiess PE, Ye DW. ASO Author Reflections: T1b Penile Cancer: An Alarm to Improve Treatment. Ann Surg Oncol. 2019 Feb.26(2):692-693. Pubmedid: 30556119.
  • Zhu Y, Gu WJ, Xiao WJ, Wang BH, Azizi M, Spiess PE, Ye DW. Important Therapeutic Considerations in T1b Penile Cancer: Prognostic Significance and Adherence to Treatment Guidelines. Ann Surg Oncol. 2019 Feb.26(2):685-691. Pubmedid: 30565040.
  • Slongo J, Giuliano AR, Johnstone PA, Spiess PE. The relationship between HPV and penile cancer: Filling a knowledge gap in the general population. Can Urol Assoc J. 2019 Feb.13(2):38. Pubmedid: 30721126. Pmcid: PMC6363573.
  • Spiess PE. Updates on the Management of Rare Genitourinary Malignancies: Where Do We Stand?. Eur Urol Focus. 2019 Feb.5(5):701. Pubmedid: 30772359.
  • Chipollini J, De la Rosa AH, Azizi M, Shayegan B, Zorn KC, Spiess PE. Patient presentation, differential diagnosis, and management of penile lesions. Can Urol Assoc J. 2019 Feb.13(2 Suppl 1):S2-S8. Pubmedid: 31237837. Pmcid: PMC6620174.
  • Adashek JJ, Leonard A, Nealon SW, Krishnan A, Mosiello GC, Dhillon J, Spiess PE. Extramammary Paget's disease: what do we know and how do we treat?. Can J Urol. 2019 Dec.26(6):10012-10021. Pubmedid: 31860417.
  • Li R, Spiess PE, Gilbert SM, Necchi A. Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6. Eur Urol. 2019 Aug.76(2):e34. Pubmedid: 31056228.
  • Necchi A, Lo Vullo S, Mariani L, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ager M, Hakenberg OW, Heidenreich A, Raggi D, Catanzaro M, Salvioni R, Chipollini J, Azizi M, Spiess PE. Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. Urol Oncol. 2019 Aug.37(8):531.e7-531.e15. Pubmedid: 31053524.
  • Hoffman MS, Spiess PE. Simulated management of urinary tract injury during robotic pelvic surgery utilizing the porcine model. J Robot Surg. 2019 Apr.13(2):289-292. Pubmedid: 30014233.
  • Azizi M, Cheriyan SK, Peyton CC, Foerster B, Shariat SF, Spiess PE. Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need. CURR TREAT OPTION ON. 2019 Apr.20(5):40. Pubmedid: 30937554.
  • Yuan Z, Naghavi AO, Tang D, Kim Y, Ahmed KA, Dhillon J, Giuliano AR, Spiess PE, Johnstone PA. The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer. World J Urol. 2018 Sep.36(9):1431-1440. Pubmedid: 29589134. Pmcid: PMC7771321.
  • Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Ne. 2018 Sep.16(9):1041-1053. Pubmedid: 30181416.
  • Di Pietro G, Luu HN, Spiess PE, Sexton W, Dickinson S, Parker A, Park JY. Biomarkers and new therapeutic targets in renal cell carcinoma. Eur Rev Med Pharmacol Sci. 2018 Sep.22(18):5874-5891. Pubmedid: 30280768.
  • Zargar-Shoshtari K, Sharma P, Spiess PE. Insight into novel biomarkers in penile cancer: Redefining the present and future treatment paradigm?. Urol Oncol. 2018 Oct.36(10):433-439. Pubmedid: 29103967.
  • Peyton CC, Azizi M, Chipollini J, Ercole C, Fishman M, Gilbert SM, Juwono T, Lockhart J, Poch M, Pow-Sang JM, Spiess PE, Wiegand L, Sexton WJ. Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience. Clin Genitourin Cancer. 2018 Oct.16(5):e1003-e1013. Pubmedid: 29859736.
  • Azizi M, Peyton CC, Spiess PE. Primitive neuroectodermal tumor arising from an untreated congenital undescended testicle. Can J Urol. 2018 Oct.25(5):9530-9533. Pubmedid: 30281013.
  • Johnstone PAS, Boulware D, Djajadiningrat R, Ottenhof S, Necchi A, Catanzaro M, Ye D, Zhu Y, Nicolai N, Horenblas S, Spiess PE. Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes. Eur Urol Focus. 2018 Oct.5(5):737-741. Pubmedid: 30327282. Pmcid: PMC7771242.
  • Cindolo L, Spiess PE, Bada M, Chipollini JJ, Nyirády P, Chiodini P, Varga J, Ditonno P, Battaglia M, De Nunzio C, Tema G, Veccia A, Antonelli A, Musi G, De Cobelli O, Conti A, Micali S, Maestro MA, Olarte JQ, Diogenes E, Lima MVA, Tracey A, Guruli G, Autorino R, Sountoulides P, Schips L. Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. World J Urol. 2018 Oct.37(8):1649-1657. Pubmedid: 30377813.
  • Chipollini J, Azizi M, Peyton CC, Tang DH, Dhillon J, Spiess PE. Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma. J Kidney Cancer VHL. 2018 Oct.5(4):6-13. Pubmedid: 30386718. Pmcid: PMC6186848.
  • Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol. 2018 Nov.4(11):1535-1542. Pubmedid: 30178038. Pmcid: PMC6248089.
  • Chipollini J, Alford B, Boulware DC, Forget P, Gilbert SM, Lockhart JL, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA, Patel SY. Epidural anesthesia and cancer outcomes in bladder cancer patients: is it the technique or the medication? A matched-cohort analysis from a tertiary referral center. BMC Anesthesiol. 2018 Nov.18(1):157. Pubmedid: 30390636. Pmcid: PMC6215353.
  • Siefker-Radtke AO, Apolo AB, Bivalacqua TJ, Spiess PE, Black PC. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. J Urol. 2018 May.199(5):1129-1142. Pubmedid: 29113841.
  • Baumgarten A, Chipollini J, Yan S, Ottenhof SR, Tang DH, Draeger D, Protzel C, Zhu Y, Ye DW, Hakenberg OW, Horenblas S, Watkin NA, Spiess PE. Penile Sparing Surgery for Penile Cancer: A Multicenter International Retrospective Cohort. J Urol. 2018 May.199(5):1233-1237. Pubmedid: 29132984.
  • Chipollini J, Yan S, Ottenhof SR, Zhu Y, Draeger D, Baumgarten AS, Tang DH, Protzel C, Ye DW, Hakenberg OW, Horenblas S, Watkin NA, Spiess PE. Surgical management of penile carcinoma in situ: results from an international collaborative study and review of the literature. BJU Int. 2018 Mar.121(3):393-398. Pubmedid: 28972681.
  • Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. J Urol. 2018 Jun.199(6):1452-1458. Pubmedid: 29329894.
  • Azizi M, Peyton CC, Boulware DC, Chipollini J, Juwono T, Pow-Sang JM, Spiess PE. Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Penile Squamous Cell Carcinoma Patients Undergoing Inguinal Lymph Node Dissection. Eur Urol Focus. 2018 Jun.5(6):1085-1090. Pubmedid: 29937330. Pmcid: PMC7771277.
  • Russell CM, Lebastchi AH, Chipollini J, Niemann A, Mehra R, Morgan TM, Miller DC, Palapattu GS, Hafez KS, Sexton WJ, Spiess PE, Weizer AZ. Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy. Urology. 2018 Jul.117:95-100. Pubmedid: 29678662.
  • Chipollini J, Tang DH, Manimala N, Gilbert SM, Pow-Sang JM, Sexton WJ, Poch MA, Spiess PE. Evaluating the accuracy of intraoperative frozen section during inguinal lymph node dissection in penile cancer. Urol Oncol. 2018 Jan.36(1):14.e1-14.e5. Pubmedid: 29032883.
  • Attalla K, Paulucci DJ, Blum K, Anastos H, Moses KA, Badani KK, Spiess PE, Sfakianos JP. Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database. Urol Oncol. 2018 Jan.36(1):14.e17-14.e24. Pubmedid: 29031418.
  • Azizi M, Spiess PE. Penile cancer: Targeted therapy in penile cancer: a new treatment paradigm. Nat Rev Urol. 2018 Jan.15(1):5-6. Pubmedid: 29089608.
  • Tang DH, Chipollini J, Spiess PE. Postchemotherapy lymph node dissection for isolated retroperitoneal nodal recurrences for penile cancer: Is cure possible in highly selected cases?. Urol Oncol. 2018 Jan.36(1):1-3. Pubmedid: 29108682.
  • Chipollini J, Chaing S, Peyton CC, Sharma P, Kidd LC, Giuliano AR, Johnstone PA, Spiess PE. National Trends and Predictors of Locally Advanced Penile Cancer in the United States (1998-2012). Clin Genitourin Cancer. 2018 Feb.16(1):e121-e127. Pubmedid: 28866244.
  • Kamel MH, Tao J, Su J, Khalil MI, Bissada NK, Schurhamer B, Spiess PE, Davis R. Survival outcomes of organ sparing surgery, partial penectomy, and total penectomy in pathological T1/T2 penile cancer: Report from the National Cancer Data Base. Urol Oncol. 2018 Feb.36(2):82.e7-82.e15. Pubmedid: 29153943.
  • Ottenhof SR, Leone A, Djajadiningrat RS, Azizi M, Zargar K, Kidd LC, Diorio G, Mosiello G, Graafland NM, Spiess PE, Horenblas S. Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer. Eur Urol Focus. 2018 Feb.5(5):867-874. Pubmedid: 29433986.
  • Marchioni M, Berardinelli F, De Nunzio C, Spiess P, Porpiglia F, Schips L, Cindolo L. New insight in penile cancer. Minerva Urol Nefrol. 2018 Dec.70(6):559-569. Pubmedid: 30230297.
  • Peyton CC, Chipollini J, Azizi M, Kamat AM, Gilbert SM, Spiess PE. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. World J Urol. 2018 Dec.37(10):2017-2029. Pubmedid: 30535583.
  • Chipollini J, Necchi A, Spiess PE. Outcomes for Patients with Node-positive Penile Cancer: Impact of Perioperative Systemic Therapies and the Importance of Surgical Intervention. Eur Urol. 2018 Aug.74(2):241-242. Pubmedid: 29730019.
  • Tang DH, Yan S, Ottenhof SR, Draeger D, Baumgarten AS, Chipollini J, Protzel C, Zhu Y, Ye DW, Hakenberg OW, Horenblas S, Watkin NA, Spiess PE. Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis. Urol Oncol. 2018 Apr.36(4):147-152. Pubmedid: 29097087.
  • Mir MC, Matin SF, Bex A, Spiess PE, Thompson RH, Grob B, van Poppel H. The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. Minerva Urol Nefrol. 2018 Apr.70(2):109-125. Pubmedid: 29381020.
  • Li R, Spiess PE, Kamat AM. Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?. Eur Urol. 2018 10.74(4):405-408. Pubmedid: 29685644.
  • Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2017 Oct.15(10):1240-1267. Pubmedid: 28982750.
  • Baumgarten AS, Fisher JS, Lawindy SM, Pavlinec JG, Carrion RE, Spiess PE. Penile sparing surgical approaches for primary penile tumors: preserving function and appearance. Transl Androl Urol. 2017 Oct.6(5):809-819. Pubmedid: 29184777. Pmcid: PMC5673820.
  • Kidd LC, Chaing S, Chipollini J, Giuliano AR, Spiess PE, Sharma P. Relationship between human papillomavirus and penile cancer-implications for prevention and treatment. Transl Androl Urol. 2017 Oct.6(5):791-802. Pubmedid: 29184775. Pmcid: PMC5673821.
  • Spiess PE, Poch MA. Management of penile cancer. Transl Androl Urol. 2017 Oct.6(5):783-784. Pubmedid: 29184773. Pmcid: PMC5673816.
  • Zargar H, Shah JB, van de Putte EEF, Potvin KR, Zargar-Shoshtari K, van Rhijn BW, Daneshmand S, Holzbeierlein JM, Spiess PE, Winquist E, Horenblas S, Dinney C, Black PC, Kassouf W. Dose dense MVAC prior to radical cystectomy: a real-world experience. World J Urol. 2017 Nov.35(11):1729-1736. Pubmedid: 28625005.
  • Tang DH, Yan S, Ottenhof SR, Draeger D, Baumgarten AS, Chipollini J, Protzel C, Zhu Y, Ye DW, Hakenberg OW, Horenblas S, Watkin NA, Spiess PE. Glansectomy as Primary Management of Penile Squamous Cell Carcinoma: An International Study Collaboration. Urology. 2017 Nov.109:140-144. Pubmedid: 28818536.
  • Ottenhof SR, Leone AR, Horenblas S, Spiess PE, Vegt E. Advancements in staging and imaging for penile cancer. Curr Opin Urol. 2017 Nov.27(6):612-620. Pubmedid: 28937510.
  • Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ. Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. Oncotarget. 2017 Nov.8(58):99093-99103. Pubmedid: 29228755. Pmcid: PMC5716795.
  • Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Perioperative Transfusion of Leukocyte-depleted Blood Products in Contemporary Radical Cystectomy Cohort Does Not Adversely Impact Short-term Survival. Urology. 2017 May.103:142-148. Pubmedid: 28011275.
  • Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017 Mar.35(3):379-387. Pubmedid: 27604375.
  • Lewis KM, Li Q, Jones DS, Corrales JD, Du H, Spiess PE, Lo Menzo E, DeAnda A. Development and validation of an intraoperative bleeding severity scale for use in clinical studies of hemostatic agents. Surgery. 2017 Mar.161(3):771-781. Pubmedid: 27839931.
  • Leone A, Diorio GJ, Pettaway C, Master V, Spiess PE. Contemporary management of patients with penile cancer and lymph node metastasis. Nat Rev Urol. 2017 Jun.14(6):335-347. Pubmedid: 28401957.
  • Chipollini J, Tang DH, Hussein K, Patel SY, Garcia-Getting RE, Pow-Sang JM, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Does Implementing an Enhanced Recovery After Surgery Protocol Increase Hospital Charges? Comparisons From a Radical Cystectomy Program at a Specialty Cancer Center. Urology. 2017 Jul.105:108-112. Pubmedid: 28342928.
  • McCormick B, Dahmen A, Antar A, Baumgarten A, Dhillon J, Spiess PE. Rare urologic tumors. Curr Opin Urol. 2017 Jan.27(1):68-75. Pubmedid: 27798414.
  • Leone AR, Kidd LC, Diorio GJ, Zargar-Shoshtari K, Sharma P, Sexton WJ, Spiess PE. Bilateral benign renal oncocytomas and the role of renal biopsy: single institution review. BMC Urol. 2017 Jan.17(1):6. Pubmedid: 28081704. Pmcid: PMC5234146.
  • Redrow GP, Guo CC, Brausi MA, Coleman JA, Fernandez MI, Kassouf W, Keeley FX, Margulis V, Raman JD, Roupret M, Shariat SF, Spiess PE, Thalmann GN, Matin SF. Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. J Urol. 2017 Feb.197(2):287-295. Pubmedid: 27664578.
  • Spiess PE, Diorio GJ. Editorial Comment. J Urol. 2017 Feb.197(2):396-397. Pubmedid: 27836457.
  • Chipollini J, Tang DH, Sharma P, Baumgarten AS, Spiess PE. Patterns of Regional Lymphadenectomy for Clinically Node-negative Patients With Penile Carcinoma: Analysis From the National Cancer Database From 1998 to 2012. Clin Genitourin Cancer. 2017 Dec.15(6):670-677.e1. Pubmedid: 28522287.
  • Tang DH, Nawlo J, Chipollini J, Gilbert SM, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach?. Clin Genitourin Cancer. 2017 Dec.15(6):696-703. Pubmedid: 28566202.
  • Chipollini J, Tang DH, Gilbert SM, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE. Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence-Free Survival for Patients with Penile Cancer. J Urol. 2017 Dec.198(6):1346-1352. Pubmedid: 28652123.
  • Thomas K, Spiess P, Caracciolo JT. A report of two deep-seated noncutaneous penile tumors: more than meets the eye. Radiol Case Rep. 2017 Dec.12(4):726-730. Pubmedid: 29484058. Pmcid: PMC5823293.
  • Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 Aug.198(2):281-288. Pubmedid: 28268170.
  • Chipollini J, Chaing S, Azizi M, Kidd LC, Kim P, Spiess PE. Advances in Understanding of Penile Carcinogenesis: The Search for Actionable Targets. Int J Mol Sci. 2017 Aug.18(8). Pubmedid: 28813024. Pmcid: PMC5578166.
  • Ordookhanian C, Kaloostian PE, Ghostine SS, Spiess PE, Etame AB. Management Strategies and Outcomes for VHL-related Craniospinal Hemangioblastomas. J Kidney Cancer VHL. 2017 Aug.4(3):37-44. Pubmedid: 28868236. Pmcid: PMC5573741.
  • Sharma P, Zargar-Shoshtari K, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence?. World J Urol. 2017 Apr.35(4):657-663. Pubmedid: 27495912.
  • Leone A, Inman B, Spiess PE. Need for Evidence and Consensus on Laser Treatment for Management of Select Primary Penile Tumors. Eur Urol. 2017 07.72(1):4-6. Pubmedid: 28131464.
  • Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Author Reply. Urology. 2017 05.103:148. Pubmedid: 28108090.
  • Diorio GJ, Leone AR, Spiess PE. Management of Penile Cancer. Urology. 2016 Oct.96:15-21. Pubmedid: 26802797.
  • Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Ne. 2016 Oct.14(10):1213-1224. Pubmedid: 27697976. Pmcid: PMC5379654.
  • Kumar NB, Pow-Sang JM, Spiess PE, Park JY, Chornokur G, Leone AR, Phelan CM. Chemoprevention in African American Men With Prostate Cancer. Cancer Control. 2016 Oct.23(4):415-423. Pubmedid: 27842331.
  • Sharma P, Zargar-Shoshtari K, Pettaway CA, Schabath MB, Giuliano AR, Spiess PE. Disparities in Penile Cancer. Cancer Control. 2016 Oct.23(4):409-414. Pubmedid: 27842330.
  • Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. 2016 Oct.7(43):70794-70802. Pubmedid: 28053292. Pmcid: PMC5340117.
  • Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol. 2016 Nov.34(11):1567-1573. Pubmedid: 27072536.
  • Spiess PE, Dhillon J, Baumgarten AS, Johnstone PA, Giuliano AR. Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies. CA-Cancer J Clin. 2016 Nov.66(6):481-495. Pubmedid: 27314890.
  • Spiess PE. Penile, Urethral, and Scrotal Cancer. Urol Clin North Am. 2016 Nov.43(4):xvii-xviii. Pubmedid: 27717442.
  • Sharma P, Zargar H, Spiess PE. Surgical Advances in Inguinal Lymph Node Dissection: Optimizing Treatment Outcomes. Urol Clin North Am. 2016 Nov.43(4):457-468. Pubmedid: 27717432.
  • Zargar-Shoshtari K, Zargar H, Dinney CP, Ercole CE, Sharma P, Kovac E, Grivas PD, Stephenson AJ, Shah JB, Black PC, Spiess PE. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. World J Urol. 2016 May.34(5):695-701. Pubmedid: 26286880.
  • Zargar-Shoshtari K, Sharma P, Djajadiningrat R, Catanzaro M, Ye DW, Zhu Y, Nicolai N, Horenblas S, Spiess PE. Extent of pelvic lymph node dissection in penile cancer may impact survival. World J Urol. 2016 Mar.34(3):353-359. Pubmedid: 26026817.
  • Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol Oncol. 2016 Mar.34(3):122.e1-122.e7. Pubmedid: 26546482. Pmcid: PMC4761468.
  • Sharma P, Ashouri K, Zargar-Shoshtari K, Luchey AM, Spiess PE. Racial and economic disparities in the treatment of penile squamous cell carcinoma: Results from the National Cancer Database. Urol Oncol. 2016 Mar.34(3):122.e9-122.15. Pubmedid: 26547834.
  • Russell CM, Lue K, Fisher J, Kassouf W, Schwaab T, Sexton WJ, Tanguay S, Psutka SP, Thompson RH, Leibovich BC, Hanzly MI, Spiess PE, Boorjian SA. Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma. BJU Int. 2016 Jun.117(6B):E60-E66. Pubmedid: 26118331.
  • Leone AR, Diorio GJ, Spiess PE, Gilbert SM. Contemporary Issues Surrounding Small Renal Masses: Evaluation, Diagnostic Biopsy, Nephron Sparing, and Novel Treatment Modalities. Oncology (Williston Park). 2016 Jun.30(6):507-514. Pubmedid: 27323710.
  • Leone A, Diorio G, Zargar-Shoshtari K, Spiess PE. Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Transl Androl Urol. 2016 Jun.5(3):393-395. Pubmedid: 27296873. Pmcid: PMC4893515.
  • Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, Spiess PE, Sexton WJ, Pow-Sang JM, Gilbert SM, Poch MA. Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice. Urology. 2016 Jul.93:130-134. Pubmedid: 27041469.
  • Zargar-Shoshtari K, Zargar H, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black P. A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. J Urol. 2016 Jan.195(1):53-59. Pubmedid: 26205531.
  • Sharma P, Henriksen CH, Zargar-Shoshtari K, Xin R, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy. J Urol. 2016 Jan.195(1):47-52. Pubmedid: 26235376. Pmcid: PMC4924593.
  • Dickey RM, Srikishen N, Lipshultz LI, Spiess PE, Carrion RE, Hakky TS. Augmented reality assisted surgery: a urologic training tool. Asian J Androl. 2016 Jan.18(5):732-734. Pubmedid: 26620455. Pmcid: PMC5000796.
  • Fisher JS, Gonzalez R, Spiess PE. A Novel Use of Tisseel in the Setting of Uncontrolled Bleeding in a Thrombocytopenic Patient With Idiopathic Thrombocytopenia. Urol Case Rep. 2016 Jan.4:48-50. Pubmedid: 26793579. Pmcid: PMC4719898.
  • Zargar-Shoshtari K, Sverrisson EF, Sharma P, Gupta S, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. Clin Genitourin Cancer. 2016 Feb.14(1):82-88. Pubmedid: 26411593.
  • Lue K, Russell CM, Fisher J, Kurian T, Agarwal G, Luchey A, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Predictors of Postoperative Complications in Patients Who Undergo Radical Nephrectomy and IVC Thrombectomy: A Large Contemporary Tertiary Center Analysis. Clin Genitourin Cancer. 2016 Feb.14(1):89-95. Pubmedid: 26453395.
  • Russell CM, Sharma P, Agarwal G, Fisher JS, Richard GJ, Spiess PE, Pow-Sang JM, Poch MA, Sexton WJ. Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?. Can J Urol. 2016 Feb.23(1):8127-8134. Pubmedid: 26892052.
  • Gwede CK, Davis SN, Wilson S, Patel M, Vadaparampil ST, Meade CD, Rivers BM, Yu D, Torres-Roca J, Heysek R, Spiess PE, Pow-Sang J, Jacobsen P. Perceptions of Prostate Cancer Screening Controversy and Informed Decision Making: Implications for Development of a Targeted Decision Aid for Unaffected Male First-Degree Relatives. Am J Health Promot. 2016 Dec.29(6):393-401. Pubmedid: 24968183. Pmcid: PMC4277494.
  • Zargar-Shoshtari K, Ashouri K, Sharma P, Baumgarten A, Sexton WJ, Pow-Sang J, Spiess PE. Nephrectomy and inferior vena cava thrombectomy for renal cell carcinoma among patients with impaired renal function: defining predictors of outcomes. ANZ J Surg. 2016 Dec.86(1-2):44-48. Pubmedid: 26370725.
  • Zargar H, Zargar-Shoshtari K, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black P. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?. J Urol. 2016 Apr.195(4 Pt 1):886-893. Pubmedid: 26521718.
  • Sharma P, Zargar-Shoshtari K, Spiess PE, Sexton WJ, Poch MA. Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy. Urol Ann. 2016 Apr.8(2):151-156. Pubmedid: 27141183. Pmcid: PMC4839230.
  • Gonzalez BD, Jim HS, Donovan KA, Small BJ, Sutton SK, Park J, Lin HY, Spiess PE, Fishman MN, Jacobsen PB. Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison. J Urol. 2015 Sep.194(3):690-695. Pubmedid: 25791402. Pmcid: PMC4546512.
  • Zargar-Shoshtari K, Djajadiningrat R, Sharma P, Catanzaro M, Zhu Y, Nicolai N, Horenblas S, Spiess PE. Establishing Criteria for Bilateral Pelvic Lymph Node Dissection in the Management of Penile Cancer: Lessons Learned from an International Multicenter Collaboration. J Urol. 2015 Sep.194(3):696-701. Pubmedid: 25801766.
  • Simon RM, Kim T, Espiritu P, Kurian T, Sexton WJ, Pow-Sang JM, Sverrisson E, Spiess PE. Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior vena cava tumor thrombectomy and concomitant radical nephrectomy. Int Braz J Urol. 2015 Sep.41(5):911-919. Pubmedid: 26689516. Pmcid: PMC4756967.
  • Ashouri K, Mohseni S, Tourtelot J, Sharma P, Spiess PE. Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma. J Kidney Cancer VHL. 2015 Sep.2(4):163-173. Pubmedid: 28326271. Pmcid: PMC5345519.
  • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Richard GJ, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol. 2015 Oct.33(10):1585-1592. Pubmedid: 25552207.
  • Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty JW, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn GP, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila). 2015 Oct.8(10):879-887. Pubmedid: 25873370. Pmcid: PMC4596745.
  • Sharma P, Sawar A, Spiess P. Re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular extraction of caval tumor thrombus to facilitate minimally invasive cytoreductive nephrectomy for metastatic kidney cancer. Eur Urol 2015;68:167-8. Eur Urol. 2015 Oct.68(4):e79-e80. Pubmedid: 26007640.
  • Luchey AM, Agarwal G, Espiritu PN, Lockhart JL, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA. Patient and disease-specific factors and their influence on urinary reconstruction choice at a referral center. World J Urol. 2015 Nov.33(11):1763-1768. Pubmedid: 25774005.
  • Luchey AM, Lin HY, Yue B, Agarwal G, Gilbert SM, Lockhart J, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Implications of Definitive Prostate Cancer Therapy on Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for Bladder Urothelial Cancer. J Urol. 2015 Nov.194(5):1220-1225. Pubmedid: 26055823.
  • Zargar-Shoshtari K, Sharma P, Espiritu P, Kurian T, Pow-Sang JM, Mangar D, Sexton WJ, Spiess PE. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension. Urol Oncol. 2015 Mar.33(3):112.e23-112.e29. Pubmedid: 25555854.
  • Zargar-Shoshtari K, Sharma P, Spiess PE. Re: Oliver W. Hakenberg, Eva M. Compérat, Suks Minhas, Andrea Necchi, Chris Protzel, Nick Watkin. EAU Guidelines on Penile Cancer: 2014 Update. Eur Urol 2015;67:142-50. Eur Urol. 2015 Jun.67(6):e109-e110. Pubmedid: 25530609.
  • Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun.13(3):225-230. Pubmedid: 25544725.
  • Abarzua-Cabezas FG, Sverrisson E, Cruz Rde L, Spiess PE, Haddock P, Sexton WJ. Oncological and functional outcomes of salvage renal surgery following failed primary intervention for renal cell carcinoma. Int Braz J Urol. 2015 Jun.41(1):147-154. Pubmedid: 25928521. Pmcid: PMC4752068.
  • Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, Park JY, Spiess PE, Fishman MN, Jacobsen PB. Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. J Clin Oncol. 2015 Jun.33(18):2021-2027. Pubmedid: 25964245. Pmcid: PMC4461804.
  • Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb.67(2):241-249. Pubmedid: 25257030. Pmcid: PMC4840190.
  • Matin SF, Sfakianos JP, Espiritu PN, Coleman JA, Spiess PE. Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates. J Urol. 2015 Dec.194(6):1567-1574. Pubmedid: 26094807. Pmcid: PMC4896731.
  • Gopman JM, Djajadiningrat RS, Baumgarten AS, Espiritu PN, Horenblas S, Zhu Y, Protzel C, Pow-Sang JM, Kim T, Sexton WJ, Poch MA, Spiess PE. Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. BJU Int. 2015 Aug.116(2):196-201. Pubmedid: 25777366.
  • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2015 Aug.33(8):339.e17-339.e23. Pubmedid: 26094169.
  • Zargar-Shoshtari K, Kim T, Simon R, Lin HY, Yue B, Sharma P, Spiess PE, Poch MA, Pow Sang J, Sexton WJ. Surveillance Following Nephron-Sparing Surgery: An Assessment of Recurrence Patterns and Surveillance Costs. Urology. 2015 Aug.86(2):321-326. Pubmedid: 26187013.
  • Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM. Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma. Can J Urol. 2015 Aug.22(4):7882-7889. Pubmedid: 26267026.
  • Sharma P, Spiess PE. Penile cancer: Advanced penile cancer continues to elude systemic therapy. Nat Rev Urol. 2015 Apr.12(4):185-186. Pubmedid: 25708580.
  • Sharma P, Zargar-Shoshtari K, Spiess PE. Current surgical management of penile cancer. Curr Prob Cancer. 2015 Apr.39(3):147-157. Pubmedid: 25913491.
  • Baumgarten AS, Alhammali E, Hakky TS, Espiritu PN, Pow-Sang JM, Sexton WJ, Lockhart JL, Protzel C, Hakenberg O, Muneer A, Spiess PE. Salvage surgical resection for isolated locally recurrent inguinal lymph node metastasis of penile cancer: international study collaboration. J Urol. 2014 Sep.192(3):760-764. Pubmedid: 24603104.
  • Zhao Y, Bui MM, Spiess PE, Dhillon J. Sclerosing PEComa of the kidney: clinicopathologic analysis of 2 cases and review of the literature. Clin Genitourin Cancer. 2014 Oct.12(5):e229-e232. Pubmedid: 25044147.
  • Armstrong PA, Back MR, Shames ML, Bailey CJ, Kim T, Lawindy SM, Sexton WJ, Spiess PE. Outcomes after inferior vena cava thrombectomy and reconstruction for advanced renal cell carcinoma with tumor thrombus. J Vasc Surg Venous Lymphat Disord. 2014 Oct.2(4):368-376. Pubmedid: 26993539.
  • Davis SN, Sutton SK, Vadaparampil ST, Meade CD, Rivers BM, Patel MV, Torres-Roca JF, Heysek RV, Spiess P, Pow-Sang J, Jacobsen PB, Gwede CK. Informed decision making among first-degree relatives of prostate cancer survivors: a pilot randomized trial. Contemp Clin Trials. 2014 Nov.39(2):327-334. Pubmedid: 25465497. Pmcid: PMC4274628.
  • Espiritu PN, Sverrisson EF, Sexton WJ, Pow-Sang JM, Poch MA, Dhillon J, Spiess PE. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection. Urol Oncol. 2014 Jul.32(5):619-624. Pubmedid: 24495448.
  • Rao SR, Moussly S, Pacheco M, Spiess PE, Sexton WJ. Identifying unrecognized collecting system entry and the integrity of repair during open partial nephrectomy: comparison of two techniques. Int Braz J Urol. 2014 Jul. Pubmedid: 24893916.
  • Flaherty A, Kim T, Giuliano A, Magliocco A, Hakky TS, Pagliaro LC, Spiess PE. Implications for human papillomavirus in penile cancer. Urol Oncol. 2014 Jan.32(1):53.e1-53.e8. Pubmedid: 24239463.
  • Hakky TS, Baumgarten AS, Allen B, Lin HY, Ercole CE, Sexton WJ, Spiess PE. Zonal NePhRO scoring system: a superior renal tumor complexity classification model. Clin Genitourin Cancer. 2014 Feb.12(1):e13-e18. Pubmedid: 24120084.
  • Dhillon J, Mohanty SK, Kim T, Sexton WJ, Powsang J, Spiess PE. Spectrum of renal pathology in adult patients with congenital renal anomalies-a series from a tertiary cancer center. Ann Diagn Pathol. 2014 Feb.18(1):14-17. Pubmedid: 24321461.
  • Hegarty PK, Eardley I, Heidenreich A, McDougal WS, Minhas S, Spiess PE, Watkin N, Horenblas S. Penile cancer: organ-sparing techniques. BJU Int. 2014 Dec.114(6):799-805. Pubmedid: 24053403.
  • Zheng Y, Espiritu P, Hakky T, Jutras K, Spiess PE. Predicting ease of perinephric fat dissection at time of open partial nephrectomy using preoperative fat density characteristics. BJU Int. 2014 Dec.114(6):872-880. Pubmedid: 24274617.
  • Russell CM, Espiritu PN, Kassouf W, Schwaab T, Buethe DD, Dhilon J, Sexton WJ, Poch M, Powsang JM, Tanguay S, Nayan M, Alsaadi H, Hanzly MI, Spiess PE. Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort. J Urol. 2014 Aug.192(2):350-356. Pubmedid: 24530987.
  • Agarwal G, Gupta S, Spiess PE. Novel targeted therapies for the treatment of penile cancer. Expert Opin Drug Discov. 2014 Aug.9(8):959-968. Pubmedid: 24896220.
  • Spiess PE. Reply: To PMID 24397943. Urology. 2014 Apr.83(4):950. Pubmedid: 24397942.
  • Baumgarten AS, Emtage JB, Wilder RB, Biagioli MC, Gupta S, Spiess PE. Intravesical lipiodol injection technique for image-guided radiation therapy for bladder cancer. Urology. 2014 Apr.83(4):946-950. Pubmedid: 24397940.
  • Strom TJ, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA, Biagioli MC. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy±intensity modulated radiation therapy. Radiother Oncol. 2014 Apr.111(1):126-131. Pubmedid: 24746567.
  • Protzel C, Spiess PE. Molecular research in penile cancer-lessons learned from the past and bright horizons of the future?. Int J Mol Sci. 2013 Sep.14(10):19494-19505. Pubmedid: 24077122. Pmcid: PMC3821569.
  • Agarwal G, Spiess PE. Prostate cancer: Focal cryotherapy freezes recurrent disease in its tracks. Nat Rev Urol. 2013 Oct.10(10):562-563. Pubmedid: 23979660.
  • Gupta S, Spiess PE. The prospects of pazopanib in advanced renal cell carcinoma. Ther Adv Urol. 2013 Oct.5(5):223-232. Pubmedid: 24082917. Pmcid: PMC3763778.
  • Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2013 May.11(5):594-615. Pubmedid: 23667209. Pmcid: PMC4042432.
  • Spiess PE, Horenblas S, Pagliaro LC, Biagioli MC, Crook J, Clark PE, Greenberg RE, Ercole CE. Current concepts in penile cancer. J Natl Compr Canc Ne. 2013 May.11(5):617-624. Pubmedid: 23667210.
  • Spiess PE. New treatment guidelines for penile cancer. J Natl Compr Canc Ne. 2013 May.11(5 Suppl):659-662. Pubmedid: 23704237.
  • Sverrisson EF, Espiritu PN, Spiess PE. New therapeutic targets in the management of urothelial carcinoma of the bladder. Res Rep Urol. 2013 Mar.5:53-65. Pubmedid: 24400235. Pmcid: PMC3826897.
  • Ercole CE, Pow-Sang JM, Spiess PE. Update in the surgical principles and therapeutic outcomes of inguinal lymph node dissection for penile cancer. Urol Oncol. 2013 Jul.31(5):505-516. Pubmedid: 21481617.
  • Hakky TS, Ferguson D, Spiess PE, Bradley P, Lue TF, Carrion RE. Three-dimensional mapping and comparative analysis of the distal human corpus cavernosum and the inflatable penile prosthesis. Asian J Androl. 2013 Jul.15(4):567-570. Pubmedid: 23542138. Pmcid: PMC3739224.
  • Biagioli MC, Fernandez DC, Spiess PE, Wilder RB. Primary bladder preservation treatment for urothelial bladder cancer. Cancer Control. 2013 Jul.20(3):188-199. Pubmedid: 23811703.
  • Buethe DD, Spiess PE. Current management considerations for the incidentally detected small renal mass. Cancer Control. 2013 Jul.20(3):211-221. Pubmedid: 23811705.
  • Majewski T, Spiess PE, Bondaruk J, Black P, Clarke C, Benedict W, Dinney CP, Grossman HB, Tang KS, Czerniak B. Detection of bladder cancer using proteomic profiling of urine sediments. PLoS One. 2013 Jan.7(8):e42452. Pubmedid: 22879988. Pmcid: PMC3411788.
  • Spiess PE. Editor's Comment. Int Braz J Urol. 2013 Jan.39(1):1-3. Pubmedid: 23489511.
  • Spiess PE, Levy DA, Pisters LL, Mouraviev V, Jones JS. Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry. World J Urol. 2013 Dec.31(6):1321-1325. Pubmedid: 23179729.
  • Spiess PE, Levy DA, Mouraviev V, Pisters LL, Jones JS. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model. BJU Int. 2013 Aug.112(4):E256-E261. Pubmedid: 23469778.
  • Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Ne. 2013 Apr.11(4):446-475. Pubmedid: 23584347.
  • Buethe DD, Moussly S, Lin HY, Yue B, Rodriguez AR, Spiess PE, Sexton WJ. Is the R.E.N.A.L. nephrometry scoring system predictive of the functional efficacy of nephron sparing surgery in the solitary kidney?. J Urol. 2012 Sep.188(3):729-735. Pubmedid: 22819418.
  • Lawindy SM, Kurian T, Kim T, Mangar D, Armstrong PA, Alsina AE, Sheffield C, Sexton WJ, Spiess PE. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. BJU Int. 2012 Oct.110(7):926-939. Pubmedid: 22540179.
  • Spiess PE, Buethe D. Reply. BJU Int. 2012 Oct.110(7):E328. Pubmedid: 22954032.
  • Rodriguez AR, Spiess PE. Editorial comment for Park et al. J Endourol. 2012 May.26(5):498. Pubmedid: 22214182.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Mar.33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Connors S, Chornukur G, Dickinson SI, Bai W, Williams CR, Salup R, Fu W. Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. J Cancer Sci Ther. 2012 Mar.2011(S3). Pubmedid: 22422102. Pmcid: PMC3300067.
  • Mouraviev V, Spiess PE, Jones JS. Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur Urol. 2012 Jun.61(6):1204-1211. Pubmedid: 22421081.
  • Spiess PE, Given RW, Jones JS. Achieving the 'bifecta' using salvage cryotherapy for locally recurrent prostate cancer: analysis of the Cryo On-Line Data (COLD) registry data. BJU Int. 2012 Jul.110(2):217-220. Pubmedid: 21992443.
  • Hakky T, Kim T, Rodriguez AR, Armstrong P, Mangar D, Spiess PE. Retroperitoneal lymph node dissection with concomitant IVC thrombectomy, caval wall resection, and grafting for metastatic NSGCT. Int Braz J Urol. 2012 Jan.38(1):135. Pubmedid: 22397783.
  • Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012 Jan.2(1). Pubmedid: 24533253. Pmcid: PMC3924733.
  • Spiess PE, Kurian T, Lin HY, Rawal B, Kim T, Sexton WJ, Pow-Sang JM. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. BJU Int. 2012 Dec.110(11 Pt B):E470-E474. Pubmedid: 22519938.
  • Rao SR, Correa JJ, Sexton WJ, Pow-Sang JM, Dickinson SI, Lin HY, Spiess PE. Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 2012 Dec.110(11 Pt B):E475-E480. Pubmedid: 22564727.
  • Kolla SB, Spiess PE, Sexton WJ. Interobserver reliability of the RENAL nephrometry scoring system. Urology. 2011 Sep.78(3):592-594. Pubmedid: 21782219.
  • Torrey R, Spiess PE, Pal SK, Josephson D. Role of surgery for locally advanced and metastatic renal cell carcinoma. J Natl Compr Canc Ne. 2011 Sep.9(9):985-993. Pubmedid: 21917623.
  • Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB. Kidney cancer. J Natl Compr Canc Ne. 2011 Sep.9(9):960-977. Pubmedid: 21917622.
  • Parker J, Spiess PE. Current and emerging bladder cancer urinary biomarkers. ScientificWorldJournal. 2011 May.11:1103-1112. Pubmedid: 21623456. Pmcid: PMC5720052.
  • Lawindy SM, Rodriguez AR, Horenblas S, Spiess PE. Current and future strategies in the diagnosis and management of penile cancer. Adv Urol. 2011 Jul.2011:593751. Pubmedid: 21687574. Pmcid: PMC3113410.
  • Wiegand LR, Hernandez M, Pisters LL, Spiess PE. Surgical management of lymph-node-positive prostate cancer: improves symptomatic control. BJU Int. 2011 Apr.107(8):1238-1242. Pubmedid: 20880197.
  • Spiess PE, Fishman MN. Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma. Cancer Control. 2010 Oct.17(4):269-278. Pubmedid: 20861814.
  • Kolla SB, Ercole C, Spiess PE, Pow-Sang JM, Sexton WJ. Nephron-sparing surgery for pathological stage T3b renal cell carcinoma confined to the renal vein. BJU Int. 2010 Nov.106(10):1494-1498. Pubmedid: 20230378.
  • Shinn EH, Swartz RJ, Thornton BB, Spiess PE, Pisters LL, Basen-Engquist KM. Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls. J Clin Oncol. 2010 May.28(13):2274-2279. Pubmedid: 20368572. Pmcid: PMC2860440.
  • Spiess PE. Editorial comment. Urology. 2010 Jun.75(6):1410-1411. Pubmedid: 20513502.
  • Childs MA, Wood CG, Spiess PE, Debiane LG, Hernandez M, Matin SF, Millikan RE, Siefker-Radtkie A, Scott SM, Pisters LL. Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy. Can J Urol. 2010 Jun.17(3):5184-5189. Pubmedid: 20566011.
  • Spiess PE, Katz AE, Chin JL, Bahn D, Cohen JK, Shinohara K, Hernandez M, Bossier J, Kassouf W, Pisters LL. A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer. BJU Int. 2010 Jul.106(2):194-198. Pubmedid: 19922545.
  • Taylor JM, Spiess PE, Kassouf W, Munsell MF, Kamat AM, Dinney CP, Grossman HB, Pisters LL. Management of urethral recurrence after orthotopic urinary diversion. BJU Int. 2010 Jul.106(1):56-61. Pubmedid: 20002676.
  • Spiess PE. Surgical management of locally recurrent renal cell carcinoma post-renal cryoablation: importance of stringent selection criteria. Urol Oncol. 2010 Jul.28(3):241-242. Pubmedid: 20189841.
  • Parker J, Buga S, Sarria JE, Spiess PE. Advancements in the management of urologic chronic pelvic pain: what is new and what do we know?. Curr Urol Rep. 2010 Jul.11(4):286-291. Pubmedid: 20449695.
  • Correa JJ, Hakky TS, Spiess PE, Chuang T, Sexton WJ. Robotic-assisted partial cystectomy with en bloc excision of the urachus and the umbilicus for urachal adenocarcinoma. J Robot Surg. 2010 Jan.3(4):235-238. Pubmedid: 27628636.
  • Caso J, Seigne J, Back M, Spiess PE, Pow-Sang J, Sexton WJ. Circumferential resection of the inferior vena cava for primary and recurrent malignant tumors. J Urology. 2009 Sep.182(3):887-893. Pubmedid: 19616230.
  • Correa JJ, Fishman M, Chuang ST, Spiess PE. Surgery plus targeted therapy for renal cell carcinoma with isolated spermatic cord metastasis. Clin Genitourin Cancer. 2009 Oct.7(3):E101-E103. Pubmedid: 19815479.
  • Spiess PE. "Robotic cystectomy and the internet: separating fact from fiction" by Pruthi R.S. et al. Urol Oncol. 2009 Nov.27(6):686. Pubmedid: 19879480.
  • Svatek R, Spiess P, Sundi D, Tu S, Tannir N, Brown G, Kamat A, Wood C, Pisters L. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer. 2009 Mar.115(6):1310-1317. Pubmedid: 19156903.
  • Spiess P, Pisters L, Liu P, Pettaway C, Kamat A, Gomez J, Tannir N. Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol. 2009 Jan.26(6):595-599. Pubmedid: 18367105. Pmcid: PMC4121060.
  • Williams DH 4th, Karpman E, Sander J, Spiess P, Pisters L, Lipshultz L. Pretreatment Semen Parameters in Men With Cancer. J Urology. 2009 Feb.181(2):736-740. Pubmedid: 19091343.
  • Svatek RS, Munsell M, Kincaid JM, Hegarty P, Slaton JW, Busby JE, Gaston KE, Spiess PE, Pagliaro LC, Tamboli P, Pettaway CA. Association between lymph node density and disease specific survival in patients with penile cancer. J Urology. 2009 Dec.182(6):2721-2727. Pubmedid: 19837433.
  • Spiess PE, Hernandez MS, Pettaway CA. Contemporary inguinal lymph node dissection: minimizing complications. World J Urol. 2009 Apr.27(2):205-212. Pubmedid: 18762945.
  • Gorbatiy V, Spiess PE, Pisters LL. The growing teratoma syndrome: Current review of the literature. Indian J Urol. 2009 Apr.25(2):186-189. Pubmedid: 19672343. Pmcid: PMC2710061.
  • Pettaway CA, Song R, Wang X, Sanchez-Ortiz R, Spiess PE, Strom S, Troncoso P. The ratio of matrix metalloproteinase to E-cadherin expression: a pilot study to assess mRNA and protein expression among African American prostate cancer patients. Prostate. 2008 Sep.68(13):1467-1476. Pubmedid: 18618693. Pmcid: PMC2574568.
  • Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, Lotan Y, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst. 2008 Oct.100(19):1401-1411. Pubmedid: 18812553. Pmcid: PMC2720731.
  • Kassouf W, Spiess P, Brown G, Liu P, Grossman H, Dinney C, Kamat A. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol. 2008 Jul.180(1):164-167. Pubmedid: 18485384. Pmcid: PMC5154171.
  • Kassouf W, Agarwal P, Herr H, Munsell M, Spiess P, Brown G, Pisters L, Grossman H, Dinney C, Kamat A. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 2008 Jan.26(1):121-126. Pubmedid: 18165646.
  • Leibovici D, Spiess P, Heller L, Rodriguez-Bigas M, Chang G, Pisters L. Salvage surgery for locally recurrent prostate cancer after radiation therapy: tricks of the trade. Urol Oncol. 2008 Jan.26(1):9-16. Pubmedid: 18190824.
  • Spiess P, Busby J, Jordan J, Steinberg J, Bassett R, Davuluri R, Burt K, Troncoso P, Lee A, Taylor S, Pisters L. Can digital rectal examination or transrectal ultrasonography biopsy findings predict the side of nodal metastasis in prostate cancer?. Urol Oncol. 2008 Feb.26(1):25-30. Pubmedid: 18190826.
  • Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, Kamat AM. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol. 2007 Sep.52(3):769-774. Pubmedid: 17434254. Pmcid: PMC2691552.
  • Spiess P, Pettaway C, Vakar-Lopez F, Kassouf W, Wang X, Busby J, Do K, Davuluri R, Tannir N. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer. 2007 Oct.110(8):1729-1737. Pubmedid: 17786954.
  • Spiess P, Tuziak T, Tibbs R, Bassett R, Tamboli P, Brown G, Grossman H, Ayala A, Czerniak B. Pseudosarcomatous and sarcomatous proliferations of the bladder. Hum Pathol. 2007 May.38(5):753-761. Pubmedid: 17306332.
  • Kassouf W, Sanchez-Ortiz R, Tamboli P, Jonasch E, Merchant M, Spiess P, WoodCG. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. Urology. 2007 May.69(5):835-838. Pubmedid: 17482917.
  • Zorn K, Spiess P, Singh G, Orvieto M, Moore B, Corcos J. Long-term tensile properties of tension-free vaginal tape, suprapubic arc sling system and urethral sling in an in vivo rat model. J Urology. 2007 Mar.177(3):1195-1198. Pubmedid: 17296444.
  • Spiess P, Izawa J, Bassett R, Kedar D, Busby J, Wong F, Eddings T, TamboliP, Pettaway C. Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urol. 2007 Jun.177(6):2157-2161. Pubmedid: 17509308.
  • Spiess P, Brown G, Liu P, Tu S, Tannir N, Evans J, Kamat A, Kassouf W, Pisters L. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urology. 2007 Jan.177(1):131-138. Pubmedid: 17162023.
  • Leibovici D, Spiess P, Agarwal P, Tu S, Pettaway C, Hitzhusen K, MillikanRE, Pisters L. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer. 2007 Jan.109(2):198-204. Pubmedid: 17171704.
  • Tuziak T, Spiess P, Abrahams N, Wrona A, Tu S, Czerniak B. Multilocular cystadenoma and cystadenocarcinoma of the prostate. Urol Oncol. 2007 Jan.25(1):19-25. Pubmedid: 17208134.
  • Spiess P, Kassouf W, Steinberg J, Tuziak T, Hernandez M, Tibbs R, CzerniakB, Kamat A, Dinney C, Grossman H. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol. 2007 Jan.25(1):38-45. Pubmedid: 17208137.
  • Spiess P, Lee A, Busby J, Jordan J, Hernandez M, Burt K, Troncoso P, Merriman K, Pisters L. Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome. Bju Int. 2007 Feb.99(2):321-325. Pubmedid: 17155975.
  • Spiess P, Tannir N, Tu S, Brown G, Liu P, Kamat A, Wood C, Evans J, Pisters L. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression. Cancer. 2007 Dec.110(12):2700-2708. Pubmedid: 17948916.
  • Spiess P, Tannir N, Brown G, Liu P, Tu S, Evans J, Pisters L. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology. 2007 Dec.70(6):1173-1178. Pubmedid: 18158041.
  • Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer. 2007 Aug.110(4):764-769. Pubmedid: 17614317.
  • Lee S, Jeong J, Majewski T, Scherer SE, Kim MS, Tuziak T, Tang KS, Baggerly K, Grossman HB, Zhou JH, Shen L, Bondaruk J, Ahmed SS, Samanta S, Spiess P, Wu X, Filipek S, McConkey D, Bar-Eli M, Issa JP, Benedict WF, Czerniak B. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc Natl Acad Sci U S A. 2007 Aug.104(34):13732-13737. Pubmedid: 17702869. Pmcid: PMC1949496.
  • Spiess P, Kassouf W, Brown G, Kamat A, Liu P, Gomez J, Tu S, Tannir N, Pisters L. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urology. 2007 Apr.177(4):1330-1334. Pubmedid: 17382725.
  • Bermejo C, Busby J, Spiess P, Heller L, Pagliaro L, Pettaway C. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urology. 2007 Apr.177(4):1335-1338. Pubmedid: 17382727.
  • Shinn EH, Basen-Engquist K, Thornton B, Spiess PE, Pisters L. Health behaviors and depressive symptoms in testicular cancer survivors. Urology. 2007 Apr.69(4):748-753. Pubmedid: 17445663. Pmcid: PMC2674069.
  • Spiess P, Grossman H. Fluorescence cystoscopy: is it ready for use in routine clinical practice?. Curr Opin Urol. 2006 Sep.16(5):372-376. Pubmedid: 16905985.
  • Spiess P, Brown G, Pisters L, Liu P, Tu S, Evans J, Kamat A, Black P, Tannir N. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?. Cancer. 2006 Oct.107(7):1503-1510. Pubmedid: 16944534.
  • Spiess P, Brown G, Liu P, Tannir N, Tu S, Evans J, Czerniak B, Kamat A, Pisters L. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer. 2006 Oct.107(7):1483-1490. Pubmedid: 16944541.
  • Evans J, Spiess P, Kamat A, Wood C, Hernandez M, Pettaway C, Dinney C, Pisters L. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urology. 2006 Oct.176(4 Pt 1):1463-1467. Pubmedid: 16952661.
  • Spiess P, Leibovici D, Pisters L. Surgery for locally advanced disease. Curr Urol Rep. 2006 May.7(3):209-216. Pubmedid: 16630524.
  • Spiess P, Kassouf W, Brown G, Highshaw R, Wang X, Do K, Kamat A, CzerniakB, Dinney C, Grossman H. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?. Urology. 2006 Mar.67(3):466-471. Pubmedid: 16527559.
  • Spiess P, Czerniak B. Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med. 2006 Jun.130(6):844-852. Pubmedid: 16740038.
  • Zorn K, Spiess P, Ross P, Taguchi Y, Aprikian A. Resident involvement in open radical prostatectomy: a review of urology surgical training. Can J Urol. 2006 Jun.13(3):3164-3168. Pubmedid: 16813710.
  • Spiess P, Lee A, Leibovici D, Wang X, Do K, Pisters L. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer. 2006 Jul.107(2):275-280. Pubmedid: 16770783.
  • Taylor S, Merriman K, Spiess P, Pisters L. Inadequacies of the current American Joint Committee on cancer staging system for prostate cancer. Cancer. 2006 Feb.106(3):559-565. Pubmedid: 16369982.
  • Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 2006 Aug.12(15):4671-4677. Pubmedid: 16899617.
  • Spiess P, Kassouf W, Tukaram K, Roy I. Metastatic umbilical mass from transitional cell carcinoma of the bladder. Can J Urol. 2005 Oct.12(5):2856-2858. Pubmedid: 16274525.
  • Leibovici D, Lee A, Cheung R, Spiess P, Kuban D, Rosser C, Shen Y, YangY, Chichakli R, Pisters L. Symptomatic local recurrence of prostate carcinoma after radiation therapy. Cancer. 2005 May.103(10):2060-2066. Pubmedid: 15822114.
  • Spiess P, Tuziak T, Kassouf W, Grossman H, Czerniak B. Malignant mesothelioma of the tunica vaginalis. Urology. 2005 Aug.66(2):397-401. Pubmedid: 16040098.
  • Zorn K, Spiess P, Salle J, Jednak R. Mucocolpos associated with bladder exstrophy: a case report. Can J Urol. 2005 Apr.12(2):2614-2615. Pubmedid: 15877945.
  • Spiess P, Rabah D, Herrera C, Singh G, Moore R, Corcos J. The tensile properties of tension-free vaginal tape and cadaveric fascia lata in an in vivo rat model. Bju Int. 2004 Jan.93(1):171-173. Pubmedid: 14678391.
  • Rabah D, Spiess P, Begin L, Corcos J. Tissue reaction of the rabbit urinary bladder to tension-free vaginal tape and porcine small intestinal submucosa. Bju Int. 2002 Oct.90(6):601-606. Pubmedid: 12230625.
  • Spiess P, Capolicchio J, Kiruluta G, Salle J, Berardinucci G, Corcos J. Is an artificial sphincter the best choice for incontinent boys with Spina Bifida? Review of our long term experience with the AS-800 artificial sphincter. Can J Urol. 2002 Apr.9(2):1486-1491. Pubmedid: 12010593.
  • Nam R, Redelmeier D, Spiess P, Sampson H, Fradet Y, Jewett M. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis. J Urology. 2000 Mar.1(3):752-757. Pubmedid: 10687970.
  • Zvara P, Spiess P, Merlin S, Begin L, Brock G. Neurogenic erectile dysfunction: the course of nicotinamide adenine dinucleotide phosphate diaphorase-positive nerve fibers on the surface of the prostate. Urology. 1996 Jan.47(1):146-151. Pubmedid: 8560654 .
  • Spiess P, Dion S, Zvara P, Merlin S, Chan P, Brock G. 7-Nitroindazole: a selective inhibitor of penile erection: an in vivo study in a rat animal model. Urology. 1996 Jan.47(1):93-96. Pubmedid: 8560670 .
  • Spiess PE, Tannir NM. Reply. Urol Oncol. 27(2):218-219. Pubmedid: 19285239.
  • Caso JR, Rodriguez AR, Correa J, Spiess PE. Update in the management of penile cancer. Int Braz J Urol. 35(4):406-415. Pubmedid: 19719855.
  • Spiess PE, Correa JJ. Robotic assisted laparoscopic partial cystectomy and urachal resection for urachal adenocarcinoma. Int Braz J Urol. 35(5):609. Pubmedid: 19860941.
  • Sexton WJ, Spiess PE, Pisters LL, Carpenter S, Madsen LT, Zagone R, Wang X, Troncoso P. Are there differences in zonal distribution and tumor volume of prostate cancer in patients with a positive family history?. Int Braz J Urol. 36(5):571-582. Pubmedid: 21044374.
  • Rodriguez AR, Hakky T, Spiess PE. Laparo-endoscopic single site retroperitoneal partial nephrectomy: a novel concept. Int Braz J Urol. 37(1):136. Pubmedid: 21506441.
  • Hakky TS, Espiritu P, Rodriguez AR, Gould N, Spiess PE. Surgical management of a locally advanced symptomatic recurrence of penile sarcoma secondary to prostate brachytherapy. Int Braz J Urol. 39(2):293-294. Pubmedid: 23683678.
  • Spiess PE. Transurethral neo-orifice (TUNO) approach to managing upper pole renal obstruction. Int Braz J Urol. 40(1):1-2. Pubmedid: 24642145.
  • Baumgarten AS, Hakky TS, Carrion RE, Lockhart JL, Spiess PE. A single-institution experience with metallic ureteral stents: a cost-effective method of managing deficiencies in ureteral drainage. Int Braz J Urol. 40(2):225-231. Pubmedid: 24856490.
  • Freilich JM, Spiess PE, Biagioli MC, Fernandez DC, Shi EJ, Hunt DC, Gupta S, Wilder RB. Lipiodol as a fiducial marker for image-guided radiation therapy for bladder cancer. Int Braz J Urol. 40(2):190-197. Pubmedid: 24856485.
  • Sverrisson EF, Kim T, Espiritu PN, Sexton WJ, Pow-Sang JM, Dhillon J, Spiess PE. The merits of cytology in the workup for upper tract urothelial carcinoma - a contemporary review of a perplexing issue. Int Braz J Urol. 40(4):493-498. Pubmedid: 25251966.
  • Wallen JJ, Baumgarten AS, Kim T, Hakky TS, Carrion RE, Spiess PE. Optimizing penile length in patients undergoing partial penectomy for penile cancer: novel application of the ventral phalloplasty oncoplastic technique. Int Braz J Urol. 40(5):708-709. Pubmedid: 25498284.
  • Rao SR, Moussly S, Pacheco M, Spiess PE, Sexton WJ. Identifying unrecognized collecting system entry and the integrity of repair during open partial nephrectomy: comparison of two techniques. Int Braz J Urol. 40(5):637-643. Pubmedid: 25498274.
  • Spiess PE. Editor's Comment - Best videos of the year for the International Brazilian Journal of Urology 2014. Int Braz J Urol. 41(3):406-407. Pubmedid: 26200532. Pmcid: PMC4752130.
  • Spiess PE. Editorial Comment: Lapar oscopic radical nephrectomy with inferior vena cava thrombectomy: highlight of key surgical steps. Int Braz J Urol. 42(4):858. Pubmedid: 27564307. Pmcid: PMC5006792.
  • Tang DH, Spiess PE. Should routine neonatal circumcision be a policy to prevent penile cancer? | Opinion: No. Int Braz J Urol. 43(1):10-12. Pubmedid: 28124520. Pmcid: PMC5293377.
  • Spiess PE. Selection of best videos of the year for 2016. Int Braz J Urol. 43(2):182-183. Pubmedid: 28328185. Pmcid: PMC5433353.
  • Spiess PE. Best videos of the year in 2017. Int Braz J Urol. 44(1):2-3. Pubmedid: 29424505. Pmcid: PMC5815525.


Title: Advancements in HPV-related Penile Cancer
Sponsor: Evans Fdtn.
PI: Spiess, P.

Patient Comments
Overall Satisfaction

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments